White Paper

C-QTc and C-QT Analysis: Replacing TQT Studies and Accelerating Cardiovascular Safety Decisions

Replace or waive TQT studies with validated C-QT analysis strategies accepted by FDA, EMA, PMDA.…

CertaraOctober 3, 2025

Case Study

Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer

Certara’s support enabled fast-track FDA oncology approval 2025 for Sunvozertinib, a breakthrough NSCLC therapy targeting…

CertaraOctober 2, 2025

Publication

Pharmacokinetics, Bioequivalence, and Safety of Bromocriptine Mesylate Tablets in Healthy Chinese Subjects

Explore how fed‑condition crossover study confirms bromocriptine mesylate bioequivalence and safety, analysed using Phoenix WinNonlin.

CertaraSeptember 29, 2025

Publication

Pharmacokinetics, Relative Bioavailability, and Safety of the SHR0302 Oral Solution and Tablets: A Single-Center, Randomized, Open-Label, Crossover (Two-Formulation, Two-Period) Phase I Trial in Healthy Chinese Volunteers

Discover how oral solution and tablet formulations of SHR0302 show comparable bioavailability and safety in…

CertaraSeptember 26, 2025

Publication

ADPO: automatic-differentiation-assisted parametric optimization

See how Automatic differentiation reduces PK/PD model runtime by up to 95% while preserving accuracy,…

CertaraSeptember 22, 2025

Blog

Best practices in clinical pharmacology gap analysis

September 19, 2025 Submitting your New Drug Application (NDA) to the FDA is the ultimate…

CertaraSeptember 19, 2025

Announcement

Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool

RADNOR, Pa. – September 17, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in…

CertaraSeptember 17, 2025

Conference

Redefining Every Stage of Investment (RESI) Seed to Exit

–

CertaraSeptember 5, 2025

Conference

The Pharmacometrics Africa Conference 2025 (PMXAC-2025)

CertaraSeptember 4, 2025

Live Events

Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies

– London, UK

CertaraSeptember 4, 2025

Modeling and Simulation

C-QTc and C-QT Analysis: Replacing TQT Studies and Accelerating Cardiovascular Safety Decisions

Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer

Pharmacokinetics, Bioequivalence, and Safety of Bromocriptine Mesylate Tablets in Healthy Chinese Subjects

Pharmacokinetics, Relative Bioavailability, and Safety of the SHR0302 Oral Solution and Tablets: A Single-Center, Randomized, Open-Label, Crossover (Two-Formulation, Two-Period) Phase I Trial in Healthy Chinese Volunteers

ADPO: automatic-differentiation-assisted parametric optimization

Best practices in clinical pharmacology gap analysis

Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool

Redefining Every Stage of Investment (RESI) Seed to Exit

The Pharmacometrics Africa Conference 2025 (PMXAC-2025)

Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies

Newsletter sign up

Quick links

Solutions

Contact